Antidepressant induced cholestasis: Hepatocellular redistribution of multidrug resistant protein (MRP2)

Gut

Volumn 52, Issue 2, 2003, Pages 300-303

  Milkiewicz, P ^a,b   Chilton, A P ^a,b   Hubscher, S G ^c   Elias, E ^a,b  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b POMERANIAN MEDICAL UNIVERSITY   (Poland)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANION; BILIRUBIN GLUCURONIDE; CITALOPRAM; DOSULEPIN; DRUG METABOLITE; MULTIDRUG RESISTANT PROTEIN; PAROXETINE; PROTEIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ADAPTATION; ADULT; ARTICLE; BASOLATERAL MEMBRANE; BILE SECRETION; CASE REPORT; CELLULAR DISTRIBUTION; CHOLESTASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOWN REGULATION; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER CELL; MALE; PREGNANCY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TIME;

ACUTE DISEASE; ADULT; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BIOPSY; CHOLESTASIS; CITALOPRAM; DOTHIEPIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER; MALE; MIDDLE AGED; MITOCHONDRIAL PROTEINS; PAROXETINE; PREGNANCY; PREGNANCY COMPLICATIONS; RIBOSOMAL PROTEINS; SACCHAROMYCES CEREVISIAE PROTEINS;

EID: 0037303901     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.52.2.300     Document Type: Article

References (16)

1. Larrey D, Amouyal G, Pessayre D, et al. Amitriptiline-induced prolonged jaundice. Gastroenterology 1988;94:200-3.
2. Randeva HS, Bangar V, Sailesh S, et al. Fatal cholestatic jaundice associated with amitriptiline. Int J Clin Pract 2000;54:405-6.
3. Timmings P, Lamont D. Intahepatic cholestasis associated with moclobemide leading to death. Lancet 1996;347:762-3.
4. DeMan RA. Severe hepatitis attributed to paroxetine. Ned Tijdschr Geneeskd 1997;141:540-2.
5. Benbow SJ, Gill G. Paroxetine and hepatotoxicity. BMJ 1997;314:1387.
6. Boyer JL. Advancing the bile-ology of cholestatic liver disease. Hepatology 2001;33:758-9.
7. Cosme A, Barrio J, Lobo C, et al. Acute cholestasis by fluoxetine. Am J Gastroenterol 1996;91:2449-50.
8. Safraz A, Cook M. Sulpiride-induced cholestatic jaundice. Aus NZ J Psychiatry 1996;30:701-2.
9. Melzer E, Knobel B. Severe cholestatic jaundice due to sulpiride. Isr J Med Sci 1987;23:1259-60.
10. Elias E, Boyer JL. Mechanisms of intrahepatic cholestasis. Prog Liver Dis 1979;6:457-70.
11. Trauner M, Arrese M, Soroka CJ, et al. The rat canalicular conjugate export pump (Mrp2) is down-regulated in intrahepatic and obstructive cholestasis. Gastroenterology 1997;113:255-64.
12. Kubitz R, Huth C, Schmitt M, et al. Protein kinase C dependent distribution on multidrug resistant protein 2 from the canalicular to the basolateral membrane in human HepG2 cells. Hepatology 2001;34:340-50.
13. Boyer JL, Soroka CJ. Vesicle targeting to the apical domain regulates bile excretory function in isolated rat hepatocyte couplets. Gastroenterology 1995;109:1600-11.
14. Milkiewicz P, Elias E, Williams A, et al. Changes in the distribution of hepatocellular transporters in end-stage cholestatic liver disease. Hepatology 2001;34:A.
15. Jacquemin E, Cresteil D, Manouvrier S, et al. Heterozygous non-sense mutation of the MDR3 gene in familial intrahepatic cholestasis of pregnancy. Lancet 1999;353:210-11.
16. Dixon PH, Weerasekera N, Linton KJ, et al. Heterozygous MDR3 missense mutation associated with intrahepatic cholestasis of pregnancy: evidence for a defect in protein trafficking. Hum Mol Genet 2000;9:1209-17.